Search with one or more keywords

This page gives you access to all the studies carried out by French researchers, identified on Covid-19.

To view other resources related to Covid-19, click here.

xml
XML

Export to XML

Please choose the format :

XML
XML-DDI
pdf
PDF

Export to PDF

Which version do you want to export ?

Download full content
Download light content
csv
CSV (Excel)

Export to CSV

What sections do you want to export ?

Métadonnées
Identification
General Aspects
Scientific investigator(s) (Contact)
Collaborations
Funding
Governance of the database
Additional contact
Type of database
Database objective
Population type
Dates
Size of the database
Data
Procedures
Promotion
Access
Select all | Invert selection | No selection
Export to CSV

ARCHIVES : 309 forms

Sorting of results :

EULEVp - Effectiveness and Use of Levetiracetam of pediatrics in real life

Head : Fourrier-Reglat Annie, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen
Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Version 2
Voir
View
Overview

139

Last update : 10/26/2017

ARCHIVE

EULEVp - Effectiveness and Use of Levetiracetam of pediatrics in real life

Head : Fourrier-Reglat Annie, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen
Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Main objective

The objectives of this study were to describe the children initiating treatment with levetiracetam, the prescribing patterns, and to evaluate the effectiveness of levetiracetam in a real situation in terms of treatment retention for one year.

Inclusion criteria

Patient aged under 16 years; Obtainment of consent from the guardian of the child; patient having initiated treatment with levetiracetam between 01/10/2006 and 31/03/2007 (whether or not the treatment was continued), and having never been previously treated with levetiracetam; patient who may be followed over the following 12 months; Patient not participating in a clinical trial (Huriet-Sérusclat).

Last update : 10/26/2017

Voir
View

EDITH - Observational study to evaluate educational modality of type 2 diabetic patients at the time of insulin initiation by GPs

Head : Vignal Franck, Sanofi Aventis

Version 1
Voir
View
Overview

140

Last update : 01/01/2018

ARCHIVE

EDITH - Observational study to evaluate educational modality of type 2 diabetic patients at the time of insulin initiation by GPs

Head : Vignal Franck, Sanofi Aventis

Main objective

describe the effects on the fasting glucose at 1 month for main methods of education of type-2 diabetes patients during the initiation of insulin therapy in general practice

Inclusion criteria

man or woman, over the age of 18 years, having a type-2 diabetes responding to the criteria of HAS (French National Authority for Health), treated with oral diabetes medication at the maximum dose (or maximum tolerated dose where applicable), having needed the adding of a basal insulin initiated since at least 1 month and no more than 6 months (+ 1 week) before inclusion, reviewed 1 month after the initiation of insulin, during a routine visit in the framework of following his or her diabetes, accepting to participate in the study after information given by the observing doctor.

Last update : 01/01/2018

Voir
View

POSTEPI - Management of osteoporosis and associated quality of life in post menopausal women

Head : Leclerc-Zwirn Christel, Laboratoire GSK

Version 1
Voir
View
Overview

141

Last update : 01/01/2018

ARCHIVE

POSTEPI - Management of osteoporosis and associated quality of life in post menopausal women

Head : Leclerc-Zwirn Christel, Laboratoire GSK

Main objective

In the framework of the new screening and reimbursement conditions for osteoporosis medications, describe the profile of postmenopausal women with osteoporosis and treated for less than 6 months

Inclusion criteria

Postmenopausal women diagnosed with osteoporosis less than 6 months ago via low BMD (Femoral total T score and/or spinal average <-2.5) or on a fracture not linked to a major trauma or to a cancer and treated for less than 6 months

Last update : 01/01/2018

Voir
View

EULEV - Effectiveness and Use of Levetiracetam in Real Life

Head : Fourrier-Reglat Annie, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen
Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Version 3
Voir
View
Overview

142

Last update : 10/26/2017

ARCHIVE

EULEV - Effectiveness and Use of Levetiracetam in Real Life

Head : Fourrier-Reglat Annie, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen
Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Main objective

The objectives of this study were to describe patients initiating treatment with levetiracetam, the prescribing patterns, and to evaluate the effectiveness of levetiracetam in a real-life situation in terms of treatment retention over one year.

Inclusion criteria

Patients who initiated treatment with levetiracetam between 01/01/2005 and 31/08/2005 or between 01/01/2006 and 31/08/2006 (irrespective of whether or not treatment was continued), and having never previously been treated with levetiracetam; patient agreeing to participate; patient can be followed over the next 12 months; Patient not participating in a clinical trial (Huriet-Sérusclat).

Last update : 10/26/2017

Voir
View

EXTRA - Observatoire sur la fréquence des manifestations EXTRA-articulaires et plus particulièrement de l'uvéite chez les patients présentant une spondylarthropathie et suivis en consultation de rhumatologie

Head : Thibout Emmanuel

Version 2
Voir
View
Overview

143

Last update : 01/01/2020

ARCHIVE

EXTRA - Observatoire sur la fréquence des manifestations EXTRA-articulaires et plus particulièrement de l'uvéite chez les patients présentant une spondylarthropathie et suivis en consultation de rhumatologie

Head : Thibout Emmanuel

Main objective

Evaluation of the frequency of extra-articular manifestations and more specifically of uveitis in patients with a spondylarthropathy

Inclusion criteria

Patients suffering from a spondylarthropathy

Last update : 01/01/2020

Voir
View

CALIPSO - Prognostic value of peripheral arterial disease on 1-year ischemic outcomes in oupatients with a recent history of ACS

Head : Herrmann Marie-Annick, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Version 1
Voir
View
Overview

144

Last update : 01/01/2019

ARCHIVE

CALIPSO - Prognostic value of peripheral arterial disease on 1-year ischemic outcomes in oupatients with a recent history of ACS

Head : Herrmann Marie-Annick, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Main objective

Determine the prognostic value of PAD (symptomatic or asymptomatic) on 1-year ischemic outcomes (death, myocardial ischemic recurrence, stroke, revascularization, rehospitalization for ischemic events) in patients with a recent ACS.

Inclusion criteria

Register part : M/F patient, >=18 years, outpatient seen by private cardiologists, with a recent history of ACS with or without ST-segment elevation in the last 12 months.
Study Part : patients from the register (2 first consecutive pts in the register without PAD) + (2 first consecutive patients in the register with symptomatic PAD or asymptomatic PAD and ABI < 0.9)

Last update : 01/01/2019

Voir
View

Please wait...

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05

View Edit Create here